Verici Dx shareholders will vote at a general meeting on 27 October 2026 on the authority needed to issue the conditional tranche of a fundraise that the company headlines at £8.75 million, after its shares returned to trading on 13 October.
Verici Dx plc (LSE:VRCI), the AIM-quoted developer of RNA-based diagnostic tests for kidney transplant patients, will hold its General Meeting at 11:30 a.m. on 27 October 2026 at Shoosmiths LLP, 1 Bow Churchyard, London, EC4M 9DQ. The meeting will seek approval of the authority for the Conditional Placing Shares. If it is passed, the Second Admission of the Conditional Placing Shares and the Retail Offer Shares is expected at 8.00 a.m. on 28 October 2026, with a long-stop date of 30 November 2026.
The vote follows a busy fortnight. Trading in the shares was suspended on 1 October 2026 under a "Capital Access Window" and restored at 7:30am on 13 October 2026, when Verici Dx announced completion of its fundraising, comprising a Placing and a WRAP Retail Offer at 0.2p per share. On 15 October the shares were at 0.215p, down 0.005p (-2.27%), on volume of 24,819,538, close to the issue price. Verici Dx is one of the stocks drawing heavy discussion among UK investors today.
Inside the fundraise
The company launched the proposed placing on 8 October 2026, initially seeking c.£8.0m gross through 4,000,000,000 shares at 0.2p. The placing was not underwritten. According to the Result of Placing announcement on 9 October 2026, it was increased "to accommodate additional interest received through the ABB" and raised £8.5 million gross from 4,250,000,000 Placing Shares at 0.20 pence. That price represented a discount of about 11.1% to the 0.225p closing mid-price on 30 September 2026.
The WRAP Retail Offer raised approximately £250,000 gross through 124,999,983 Retail Offer Shares. The completion announcement states that "the Company has raised £8.75 million through the Placing announced on 8 October 2026" and the WRAP Retail Offer. The wording is not entirely consistent across announcements, however, as the WRAP announcement text describes the combined total as "approximately £8.5 million". Put simply, the fundraise comprises an £8.5 million placing plus a retail offer of c.£250,000.
The share issue is split into two parts:
- 1,683,000,000 Firm Placing Shares, already admitted at First Admission.
- 2,567,000,000 Conditional Placing Shares, which depend on the GM vote.
- 124,999,983 Retail Offer Shares, due at Second Admission.
Total voting rights after First Admission stood at 3,970,311,387. Directors participated: Chairman Julian Baines subscribed for 10,000,000 shares and Chief Executive Officer Sara Barrington for 5,000,000 shares. Singer Capital Markets acts as Nomad and joint broker, with Oberon Capital as joint broker.
Why the money matters
The proceeds are earmarked for expanding the commercial team, marketing and key opinion leader work, laboratory capital expenditure and working capital. Management expects FY2026 Tutivia revenue of $4.75m and, if that is achieved, "anticipates that the net proceeds of the Fundraising will provide sufficient runway to achieving cash-flow breakeven by end of 2027."
Commercial momentum is the core of the case. Test orders rose c.52% in Q3 2026 compared with Q3 2025, and Tutivia is now used by 36 active transplant centres. The company processed 825 Tutivia tests in H1 (392 in Q1 and 433 in Q2) and expected Q3 orders to exceed 500. Sara Barrington, Chief Executive Officer, said in the half-year report: "We continue to increase the number of centres ordering Tutivia", adding "and I am confident that that momentum will continue into H2 2026 and beyond."
The business at a glance
Verici Dx develops AI-assisted transcriptomic (RNA) diagnostic tests for kidney transplant patients, covering the risk of injury, rejection and graft failure. Its products are Tutivia™, which is commercial, along with Protega™, PTRA (Clarava) and TranscripTx™. A Protega™ CPT® PLA code became effective on 1 October 2026, and the TranscripTx™ genetic test is due to launch by the end of FY 2026 (Q4).
The company's laboratory is in Franklin, Tennessee, in the US, on a lease running to 31 March 2030, and its registered office is in Penarth, Wales. It received New York State clinical lab certification, according to an announcement on 24 June 2026.
Financial position and register changes
The unaudited half-year report for the six months to 30 June 2026, published on 30 September 2026, showed:
- Revenue of $1.77m (H1 2025: $1.91m, which included $0.75m of licensing income).
- Tutivia revenue of $1.77m (H1 2025: $1.16m).
- Loss before tax of $4.03m (H1 2025: $3.09m) and an adjusted EBITDA loss of $3.5m.
- Cash of $2.4m at 30 June 2026 (31 Dec 2025: $3.3m), with no borrowings disclosed and lease liabilities of $0.77m.
Before the latest raise, Verici Dx (LSE:VRCI) completed a placing of c.£2.6m gross in June 2026.
Two Holding(s) in Company notices followed on 14 October 2026. Pentwater Capital Management LP reported a position of 5.138715%, held via a cash-settled swap, down from 8.919776%, with the threshold crossed on 13/10/2026. Puma AIM VCT plc, managed by Puma Investment Management Limited, reported 8.03%, or 318,928,572 voting rights out of 3,970,311,387, compared with 10.48% previously.
Risks to weigh
The fundraise reduces near-term funding pressure but introduces several risks highlighted in the company's own disclosures:
- Dilution: the placing was about 175% of the existing share capital, and 2,567,000,000 Conditional Placing Shares plus 124,999,983 Retail Offer Shares are still to be issued.
- Conditionality: the conditional tranche depends on shareholder approval at the 27 October 2026 GM.
- Funding and execution: the runway to breakeven by end-2027 depends on achieving $4.75m of FY2026 Tutivia revenue, and the half-year report notes that cash flow forecasts are "subject to uncertainty".
- Reimbursement: 68.6% of H1 2026 revenue came from Medicare and Medicaid, leaving the company exposed to US regulatory and reimbursement decisions.
The share price history underlines the volatility. Over the past 52 weeks the shares ranged between a high of 0.95p and a low of 0.20p.
What to watch next
The immediate milestones are clearly dated. The General Meeting takes place at 11:30 a.m. on 27 October 2026, and, subject to approval, Second Admission is expected at 8.00 a.m. on 28 October 2026. After that, attention is likely to turn to whether Tutivia revenue tracks the $4.75m FY2026 expectation, the scheduled TranscripTx™ launch in Q4 2026, and any further changes to the shareholder register as the enlarged share capital settles.
Verici Dx has secured fresh capital and returned to trading, but the second half of the raise still depends on shareholders. The 27 October vote is the next formal step, while the longer test is whether rising test volumes translate into the revenue that management says it needs to reach cash-flow breakeven.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...